CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...
Phase 3
Indianapolis, Indiana, United States and 7 other locations
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Indianapolis, Indiana, United States and 67 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Indianapolis, Indiana, United States and 89 other locations
and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 16 other locations
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
Indianapolis, Indiana, United States and 38 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
Indianapolis, Indiana, United States and 37 other locations
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Phase 1, Phase 2
Indianapolis, Indiana, United States and 13 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Indianapolis, Indiana, United States and 111 other locations
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...
Phase 2
Indianapolis, Indiana, United States and 64 other locations
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...
Phase 2
Indianapolis, Indiana, United States and 63 other locations
Clinical trials
Research sites
Resources
Legal